Dispatch

Insights for revenue cycle leaders

RCM trends, denial analysis, and operational strategy from the Exactrx team.

ArticleOctober 6, 2026
The Real Cost of Contesting a Claim: When $57 Chases $100

Initial denials fell in H1 2026, but payer takebacks rose 13.8%. Premier's 2023 figure of $57.23 per contested claim shows what fighting back costs.

ArticleOctober 2, 2026
The Denial Economy in 2026: What the Latest Surveys and Policy Moves Show

One in five providers now report final denial rates above 5%. What two 2026 surveys and three policy moves say about where payer friction goes next.

ArticleSeptember 29, 2026
Bots vs. Bots: What the Blue Cross AI Coding Fight Means for Your Revenue

Blue Cross says hospital AI coding added $942M in costs. Hospitals say payer AI buries them in denials. Both claims hold up.

ArticleSeptember 17, 2026
Exactrx takes home the win at the 3686 Pitch Competition

Nashville-based AI medical billing company takes top prize at the state's largest entrepreneurship conference.

InsightAugust 16, 2026
Modifier 59: When to Use It, When to Leave It Off, and the Other Modifiers That Put Your Revenue at Risk

Audit data shows 40% of modifier 59 claims fail Medicare requirements; this data-driven guide covers proper use and the underpayment patterns hiding in claims.

GuideJuly 26, 2026
Top 10 EMRs for ASCs in 2026

Nearly 1 in 4 ASCs still charts on paper. Compare the top 10 ASC EMRs, how to evaluate them, and the 5 questions to ask before you sign.

ArticleJuly 10, 2026
A CFO's guide to denial prevention, AR days, and payer contract strategy

Hospitals spent $18B fighting denials in 2025. AR days rose 5.2% anyway. Here's what the data says about why, and what to do.

ArticleJuly 7, 2026
No Surprises Act IDR Final Rule 2026: What the $15 Fee and New Batching Rules Mean for Your Dispute Strategy

The IDR admin fee drops 85% to $15 in August 2026. Here's how batching rules and a new registry reshape your dispute economics.

ArticleJuly 3, 2026
Medicare Advantage Denial Rates 2026: The Appeals Economy Reshaping Revenue Cycle Strategy

When 97% of appealed denials get overturned, the initial denial stops being clinical. Here's what that means for your RCM strategy.

ArticleJuly 2, 2026
The Checklist Top ASCs Use to Prevent 86% of Claim Denials

Denial management is now one of the costliest jobs in the revenue cycle. The groups pulling ahead score claims for denial risk before they ever reach the payer.

← PreviousPage 1 of 6Next →